Locally advanced non–small cell lung cancer: What is the optimal concurrent chemoradiation regimen?

ABSTRACT

The optimal chemoradiation regimen for patients with locally advanced non–small cell lung cancer (NSCLC) has yet to be defined. Disease and patient heterogeneity prevent a “one size fits all” approach to treatment. Concurrent chemoradiation up front is the definitive strategy for patients with unresectable stage III NSCLC; the addition of consolidation chemotherapy following definitive treatment has produced conflicting results with respect to overall survival. Biologic therapies have yet to show value as add-on treatment to chemoradiation.